AI generated article from Bing
Rituxan (rituximab) is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of patients with previously untreated and previously treated CD20-positive CLL.
The effect of RITUXAN on immune responses was assessed in a randomized, controlled study in patients with RA treated with RITUXAN and methotrexate (MTX) compared to patients treated with MTX alone.
Find info for patients about RITUXAN® (rituximab) medication for RA, NHL, CLL, GPA, MPA, and PV. See full safety and Boxed Warning for more information.
RITUXAN, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL.
591 Rituxan® (rituximab) is a genetically engineered chimeric murine/human 592 monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has 593 an approximate molecular...
Rituxan, in combination with methotrexate, is indicated for rheumatoid arthritis (RA) in adult patients with moderately to severely active RA who have had an inadequate response to one or more TNF antagonist therapies. Administer Rituxan as two 1000-mg intravenous infusions separated by 2 weeks.
RITUXAN is a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration. RITUXAN is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials.
When used as part of the Zevalin therapeutic regimen, infuse 250 mg/m 2 in accordance with the Zevalin package insert. Refer to the Zevalin package insert for full prescribing information regarding the Zevalin therapeutic regimen.
Rituxan (rituximab), in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA).
RITUXAN HYCELA is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.